Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis

Table 1

Characteristics of included studies.

Author	Trial name	Year	Treatment line	Histology	Eligible criteria for BMs	Intervention	Comparison	No. of brain metastases	Media PFS, (months)	Media OS, (months)
Horn, L.	IMpower133	2018	1	SCLC	Asymptomatic, treated	Atezolizumab + EC	Placebo + EC	17/18	5.2 VS 4.3	12.3 VS 10.3
Paz-Ares, L.	CASPAIN	2019	1	SCLC	Asymptomatic, treated	Durvalumab + EC/EP	Etoposide and EC/EP	28/27	5.1 VS 5.4	13.0 VS 10.3
Rudin, Charles M.	KEYNOTE-604	2020	1	SCLC	Untreated	Pembrolizumab + EC/EP	Placebo + EC/EP	33/22	4.5 VS 4.3	10.8 VS 9.7
Reck, M.	KEYNOTE-024	2016	1	NSCLC (NSQ/SQ)	Treated	Pembrolizumab	Platinum-based chemotherapy	18/10	10.3VS6.7	30.2 VS 14.2
Gadiel	KEYNOTE-189	2018	1	NSCLC (NSQ)	Asymptomatic	Pembrolizumab/AP	Placebo + PC/AP	73/35	8.8 VS 4.9	22.0 VS 10.7
Gadiel	OAK	2018	2	NSCLC (NSQ/SQ)	Asymptomatic, treated	Atezolizumab	Docetaxel	61/62	2.8 VS4.0	16.0 VS 11.9
H. Borghaei	CheckMate 057	2015	2	NSCLC (NSQ/SQ)	Treated, stable	Nivolumab	Docetaxel	34/34	2.3 vs 4.2	12.2 VS 9.4
Yi-Long Wu	CheckMate 078	2018	2	NSCLC (NSQ/SQ)	Treated, stable	Nivolumab	Docetaxel	45/27	2.8 vs 2.8	12.0 VS 9.6
S. Sugawara	ONO-4538-52/TASUKI-52	2021	1	NSCLC (NSQ/SQ)	Treated, stable	Nivolumab bevacizumab + TP	Bevacizumab + TP	36/41	12.1VS 8.1	25.4VS24.7
Caicun Zhou,	CameL	2021	1	NSCLC (NSQ/SQ)	Untreated	Camrelizumab + TP	Paclitaxel + TP	10/5	11.3 VS 8.3)	NR VS 20.9
Yunpeng Yang	ORIENT-11	2020	1	NSCLC (NSQ/SQ)	Asymptomatic	Sintilimab + PP	Placebo	36/22	8.9 VS 5.0	NR VS NR

NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; NR, not reported; NSQ, nonsquamous; SQ, squamous; EC, etoposide and carboplatin; EP, etoposide + cisplatin; PC, pemetrexed + carboplatin; AP, pemetrexed + cisplatin; PP, pemetrexed + platinum; TP, paclitaxel + carboplatin.